Quit Because of COVID-19 Act

Legislation and policies related to: Promotion of cessation of tobacco use and smoking, including e-cigarettes and vaping devices Preventing child and youth access to and use of tobacco products including e-cigarettes and vaping devices Stopping Consumption of Tobacco by Teens (SCOTT) Act of 2019 (H.R. 2084) Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2019 (H.R. 2339) Preventing Online Sales of E-Cigarettes to Children Act (H.R. 3942/S. 1253) Quell Underage Inhaling of Toxic Substances (QUITS) Act of 2019 (H.R. 4425) Protecting American Lungs Act (H.R. 4742) Quit Because of COVID-19 Act (H.R 7286/S. 4524) E-Cigarette Youth Protection Act (S. 616) Stopping Appealing Flavors in E-Cigarettes for Kids (SAFE Kids) Act (S. 655/H.R. 1498) Tobacco to 21 Act (S. 1258/H.R. 2411) Tobacco-Free Youth Act (S. 1541)

Client expense: Not reported · Firm income: $24,000

Government targets: Bureau of Alcohol Tobacco Firearms & Explosives, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, Veterans Affairs, Dept of (VA), Vice President of the U.S., White House Office

Newborn Screening Saves Lives Reauthorization Act Urging inclusion of children in clinical trials for COVID-19 vaccines Urging action to address the sustained decline in childhood immunization rates during COVID-19 VACCINES Act Community Immunity During COVID-19 Act FY2021 Labor, Health and Human Services, and Education Appropriations Funding within COVID-19 relief legislation to help schools safely reopen and respond to COVID-19 Keeping All Students Safe Act FY 2021 National Defense Authorization Act Marijuana Opportunity Reinvestment and Expungement (MORE) Act (H.R. 3884) CLINICAL TREATMENT Act (H.R. 913/S. 4742) Quit Because of COVID-19 Act (H.R. 7286/S. 4524) 2020 Census Deadline Extensions Act (H.R. 8250/S. 4571) COVID-19 Relief Legislation FY 2021 Appropriations The Global Child Thrive Act HEROES Act Expansion of Protecting Life in Global Health Assistance (Global Gag Rule) Consolidated Appropriations Act COVID-19 Economic Relief Bill Regulation of air pollutants Food additive safety Paid family leave Climate change IHS funding Child Abuse Prevention and Treatment Act reauthorization CAPTA Plans of safe care grants Family First Prevention Services Act implementation Issues related to the COVID-19 pandemic and providing supports for the child welfare community Emergency Funding for Child Protection Act (S 3660) Child Welfare Emergency Funding Act (S 4172) Supporting Foster Youth and Families through the Pandemic Act Scarletts Sunshine on Sudden Unexpected Death Act (H.R. 2271/S. 1130) Gun violence prevention research funding Child product safety Child passenger safety COVID-19 pandemic response for AI/AN communities Child care supplemental funding Special Diabetes Program for Indians Reauthorization Act Maternal, Infant, and Early Childhood Home Visiting Program funding Infant sleep product safety Lead exposure prevention Standards in CBP Custody, S. 2135 Standards in ICE Family Detention Standards in ORR Custody Public Charge Child Nutrition Reauthorization/WIC SNAP Mental Health for Children H.R. 6, DREAM Act Family Separation and Detention CARE for Families Act HR 3107 WIC Act Keep Families Together Act Breastfeeding Peer Counseling Program Public Health Preparedness and Response Research for Pregnant and Lactating Women Palliative Care and Hospice Education and Training Act (S. 2080) Dietary Guidelines Child Poverty HEROES Act Senate 4.0 Coronavirus Response Legislation Asylum Child Poverty Reduction Act Suicide Prevention Dr Lorna Breen Health Care Provider Protection Act S. 4349 CBP Medical Services Contract Child Nutrition Waivers School Meal Standards Universal School Meals Eviction Moratorium 12-Month Continuous Medicaid/CHIP Eligibility Medicaid Work Requirements Medicaid Block Grants Medicaid Per Capita Caps Section 1115 Medicaid Waivers Medicaid Payment Parity Increase to Medicaid FMAP During COVID-19 Establish an automatic FMAP increase tied to state economic indicators HR 6159, the Kids Access to Primary Care Act The Ensuring Access for Womens and Childrens Act, S. 4088. Medicaid Maintenance of Effort (MOE) Protections Comprehensive Access to Robust Insurance Now Guaranteed (CARING) for Kids Act (H.R.6151) Medicaid Fiscal Accountability Rule Maternal Health H.R. 4996 Helping Moms Act H.R.4995 - Maternal Health Quality Improvement Act of 2020 Expanding Medicaid to 12 Months Post-Partum Medicaid Premiums and Cost Sharing Helping Families Access Pediatric Care Act of 2020 Medicaid Payment for Eligibility Workers Expanding the use of Telehealth in Medicaid/CHIP/Private Insurance Allow for the home and other secure locations as originating (patient) and distant (provider) sites in telehealth Waive telehealth cost-sharing for patients in telehealth Pay for telehealth care visits at parity with that of in-person visits Allow telehealth care for both new and established patients Expanding Capacity for Health Outcomes (ECHO) Act of 2019 (S 1618/HR 5199) Including Preventive Medicine Service Codes to be Eligible for Telehealth Increased Access To Broadband to Expand Telehealth Services Financial Relief to Medicaid Providers Financial Relief for Pediatricians Provider Relief Fund Expanding Provider Relief Fund Eligibility to Those Pediatricians Who Received a Small Medicare Allotment COVID-19 Response Targeted allocation of funds to primary care physician practices. Expand existing alternative payment models for primary care Fully implementing the 2021 outpatient E/M changes. Immediately implement the vaccine administration payment increases proposed in the 2021 MPFS. VACCINES Act, H.R. 2862 Expand VFC to separate CHIP Programs Providing incentive payments for VFC providers Allow VFC to pay for CPT code 90461 for administering a multiple-component vaccine Allowing underinsured and uninsured children in VFC to receive a vaccine from any participating VFC provider (not just FQHC or RHC)

Client expense: $250,000 · Firm income: Not reported

Government targets: Administration for Children & Families (ACF), Agriculture, Dept of (USDA), Bureau of Citizenship & Immigration Services (BCIS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Indian Health Service, Natl Highway Traffic Safety Administration (NHTSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE)

HR 293 Youth Vaping Prevention Act of 2019; all provisions of the bill HR 1498/S 655 SAFE Kids Act; all provisions of the bill HR 1642/S 1965 Combating the Illicit Trade in Tobacco Products Act; all provisions of the bill HR 1854/S 9 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019; all provisions of the bill HR 2111PROTECT Act; Reducing Youth Use of E-Cigarettes Initiative; all provisions of the bill HR 2339Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020; all provisions of the bill HR 3942/S 1253Preventing Online Sales of E-Cigarettes to Children Act; all provisions of the bill HR 4425Quell Underage Inhaling of Toxic Substances Act of 2019; all provisions of the bill HR 4624 Ending Nicotine Dependence from Electronic Nicotine Delivery Systems Act of 2019; all provisions of the bill HR 4742Protecting American Lungs Act of 2019; all provisions of the bill HR 5721/S 3223Resources to Prevent Youth Vaping Act; all provisions of the bill HR 5963E-Cigarette Oversight and Accountability Act of 2020; all provisions of the bill HR 7286/S 4524 Quit Because of COVID-19; all provisions of the bill HR 8343Independent Advisory Committee Review of E-Cigarette Applications Act; all provisions of the bill S 616 E-Cigarette Youth Protection Act; all provisions of the bill S 1048 Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction; all provisions of the bill S 1832 Smoke-Free Schools Act of 2019; all provisions of the bill S 2517 Tobacco Tax Equity Act of 2019; all provisions of the bill S 2519 Ending New Nicotine Dependencies Act of 2019 (ENND Act); all provisions of the bill S 3174 Reversing the Youth Tobacco Epidemic Act of 2020; all provisions of the bill ANPRMS for Docket Nos. FDA-2017-N-6189, FDA-2017-N-6565, and FDA-2017-N-6107 Proposed Rule regarding Tobacco Product Standard for N-Nitrosonornicotine Level in Finished Smokeless Tobacco Products Implementation of P.L. 111-31 Family Smoking Prevention and Tobacco Control Act Discussions related to tobacco harm reduction Discussions in support of the regulation of products containing synthetic nicotine

Client expense: $2,510,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

H.R. 2339: Reversing the Youth Tobacco Epidemic Act of 2019 H.R. 7286: Quit Because of COVID-19 ACT of 2020

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Ban Surprise Billing Act (H.R. 5800) The Clinical Treatment Act (H.R. 913 / S. 4742) Consolidated Appropriations Act, 2021 (H.R. 133) Consumer Protections Against Surprise Medical Bills Act of 2020 (H.R. 5826) Dependent Income Exclusion Act of 2019 (H.R.4417/S.2497) Educating Consumers on the Risks of Short-Term Plans Act of 2019 (H.R.1143) ENROLL Act of 2019 (H.R.1386/S.1905) Family Coverage Act (S.1935) HEARTS Act of 2020 (H.R. 6166) The Heroes Act (H.R. 6800) Home Visiting to Reduce Maternal Mortality and Morbidity Act (H.R.4768) Lower Health Care Costs Act (S.1895) Maternal Health Quality Improvement Act of 2020 (HR 4995) Marketing & Outreach Restoration to Empower Health Education Act (MORE) (H.R.987) No Surprises Act (H.R.3630) The Patient Protection and Affordable Care Enhancement Act (H.R. 1425) Personal Health Investment Today Act (PHIT) (S.680/H.R.1679) Physical Activity Recommendations (PAR) for Americans Act (S.1608/H.R.2891) Pre-existing Conditions Protection Act of 2019 (H.R.692) Protect Act (S.1125) Protecting Access to Post COVID-19 Telehealth Act of 2020 (H.R. 7663) Protecting Americans with Pre-existing Conditions Act of 2019 (H.R.986) Public Health Funding Restoration Act (S.1944/H.R.3447) Quit Because of COVID-19 Act (H.R. 7286) A Resolution Supporting the Designation of April 2019 as "National Donate Life Month"(H.Res 315/S.Res 162) State Allowance for a Variety of Exchanges Act (SAVE Act) (H.R.1385) States Achieve Medicaid Expansion (S.585) State Health Care Premium Reduction Act (H.R.1425) Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019 (S.1531) Sustaining Outpatient Services Act (H.R. 4838/S.4151) Implementation of: Menu Labeling Physical Activity Guidelines Recommendations Prevention and Public Health Fund (PL 111-148, Sec 4002)

Client expense: $125,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, Veterans Affairs, Dept of (VA), White House Office

E-cigarette Tax Priority Act (S.2463) Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act (S.1048/H.R.2111) Protecting American Lungs Act of 2019 (H.R. 4742) Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020 (H.R. 2339) Quell Underage Inhalation of Toxic Substances Act of 2019 (H.R. 4425) Quit Because of COVID-19 Act (HR 7286/S. 4524) Resources to Prevent Youth Vaping Act (S. 3223/H.R. 5721) Reversing the Youth Tobacco Epidemic Act of 2020 (S. 3174) SCOTT Act of 2019 (H.R.2084) Smoke-Free Schools Act of 2019 (S.1832/H.R.4019) Stopping Appealing Flavors in E-Cigarettes for Kids (SAFE Kids) Act (S.655/H.R.1498) Tobacco-Free Youth Act (S.1541) Tobacco Tax Equity Act (S.2517) To amend title 38, U.S. Code, to prohibit smoking on the premises of any facility of the Veterans Health Administration, & for other purposes (S.2106/H.R.3700) Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 (H.R.1854/S.9) Implementation of: The Family Smoking Prevention and Tobacco Control Act (P.L.111-31) The Further Consolidated Appropriations Act of 2020 (P.L. 116-94): Division N, Sec. 603 Minimum age of sale of tobacco products and Sec. 604 Sale of tobacco products to individuals under the age of 21

Client expense: $125,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, Veterans Affairs, Dept of (VA), White House Office

Issues related to lung disease treatment, prevention and research; Issues related to tobacco cessation; Issues related to smokefree air; Issues related to Tobacco 21; Issues related to the Tobacco Control Act; Issues related to tobacco smuggling; Issues related to the Affordable Care Act; Issues related to the Presidents Budget; Issues related to tobacco prevention; Issues related to youth cessation research; Issues related to COVID-19 Response; H.R.1498 SAFE Kids Act; H.R.1854 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019; H.R.2084 SCOTT Act of 2019; H.R.2111 PROTECT Act; H.R.2339 Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020; H.R.2411 Tobacco to 21 Act; HR.3700 To amend title 38, United States Code, to prohibit smoking on the premises of any facility of the Veterans Health Administration, and for other purposes; H.R.4249 Stop Vaping Ads Act of 2019; H.R.4425 Quell Underage Inhaling of Toxic Substances Act of 2019; S.9 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019; S.616 E-Cigarette Youth Protection Act; S.655 SAFE Kids Act; S.1048 Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction; S.1253 Preventing Online Sales of E-Cigarettes to Children Act; S.1258 Tobacco to 21 Act; S.1832 Smoke-Free Schools Act of 2019; S.2106 A bill to amend title 38, United States Code, to prohibit smoking on the premises of any facility of the Veterans Health Administration, and for other purposes; S.2463 E-Cigarette Tax Parity Act; S.2517 Tobacco Tax Equity Act of 2019; S.2519 ENND Act; S.2550 No Tax Subsidies for E-Cigarette and Tobacco Ads Act; H.R.4624 Ending Nicotine Dependence from Electronic Nicotine Delivery Systems Act of 2019; H.R.4742 Protecting American Lungs Act of 2019; H.R.5005 Preventing Vape Use Act; H.R.5482 PREVENT Act of 2020; S.3096 PREVENT Act of 2020; HR 7610 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021; HR 7667 Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021; HR 7617 Department of Defense Appropriations Act, 2021; H.R.7617 Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021; H.R.7614 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021; H.R.6800 The Heroes Act; H.R.7286 Quit Because of COVID-19 Act; S. 4775 Delivering Immediate Relief to Americas Families, Schools and Small Businesses Act; Senate Labor HHS Appropriations bill;; Senate Transportation, Housing and Urban Development and Related Agencies Appropriations bill; Senate Agriculture, Rural Development, FDA, and Related Agencies Appropriations bill; H.R.133 Consolidated Appropriations Act, 2021; H.J.Res.110 - Extension of Continuing Appropriations Act, 2021

Client expense: $40,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Postal Regulatory Commission, SENATE, Small Business Administration (SBA), Treasury, Dept of, White House Office

Issues related to lung disease treatment, prevention and research; public health; Issues related to tobacco cessation; Issues related to health inequities; Issues related to the President's Budget; Issues related to Medicaid waivers; Issues related to the Affordable Care Act; Issues related to oxygen; Issues related to access to healthcare; Issues related to COVID-19 Response; H.R.2508 Better Respiration through Expanding Access to Tele-Health Act; HR 3 Elijah E. Cummings Lower Drug Costs Now Act; S 2543 Prescription Drug Pricing Reduction Act of 2019; S 2911 Seniors Prescription Drug Relief Act of 2019; HR 7610 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021; HR 7667 Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021; HR 7617 Department of Defense Appropriations Act, 2021;; HR 7614 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021; HR 7609 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021; HR 7616 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2021; HR 7608 HR 4945 Safeguarding Medicare Access to Respiratory Therapy Act of 2019; HR 6800 HEROES Act; HR 7286 Quit Because of COVID-19 Act; S. 4775 Delivering Immediate Relief to Americas Families, Schools and Small Businesses Act; S. 4321 The Continuing Small Business Recovery and Paycheck Protection Program Act; S. 4318 The American Workers, Families, and Employers Assistance Act; S. 4317 SAFE TO WORK Act; S. 4322 The Safely Back to School and Back to Work Act; S. 4320 Coronavirus Response Additional Supplemental Appropriations Act, 2020; H.R.8406 The Heroes Act; H.R.925 The Heroes Act; S.4557 COVER Act; H.R.6201 Families First Coronavirus Response Act; H.R.748 CARES Act; S.4355 Katherine's Lung Cancer Early Detection and Survival Act of 2020; H.R.8158 To amend title XVIII of the Social Security Act to waive budget neutrality for oxygen under the Medicare program, and for other purposes; H.R.8623 SAVE for Seniors Act; S.4864 HAPI Act; H.R.8725 HAPI Act; Senate Labor HHS Appropriations bill; Defense Appropriations bill; Senate Transportation, Housing and Urban Development and Related Agencies Appropriations bill; Senate Agriculture, Rural Development, FDA, and Related Agencies Appropriations bill; Senate Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021H.R.133 Consolidated Appropriations Act, 2021; H.J.Res.110 - Extension of Continuing Appropriations Act, 2021

Client expense: $40,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Postal Regulatory Commission, SENATE, Small Business Administration (SBA), Treasury, Dept of, White House Office

: Issues related to lung disease treatment, prevention and research; public health; Issues related asthma; COPD; influenza; lung cancer; pneumonia; tuberculosis and other lung diseases; Issues related to tobacco cessation; Issues related to the Affordable Care Act; Issues related to the Childrens Health Insurance Program; Issues related to the President's Budget; Issues related to telehealth; Issues related to changing federal poverty line calculation; Issues related to COVID-19 Response;; H.R.986 Protecting Americans with Preexisting Conditions Act of 2019 H.R.987 Strengthening Health Care and Lowering Prescription Drug Costs Act H.R.1010 To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect. H.R.1385 SAVE Act H.R.1386 ENROLL Act of 2019 H.R.1425 State Health Care Premium Reduction Act H.R.1499 Protecting Consumer Access to Generic Drugs Act of 2019 H.R.1884 Protecting Pre-Existing Conditions and Making Health Care More Affordable Act of 2019 H.R.2508 Better Respiration through Expanding Access to Tele-Health Act;H.R.2862 VACCINES Act of 2019; H.R.3630 No Surprises Act H.R.4622 Family Asthma Act S.466 Protecting Americans with Pre-existing Conditions Act of 2019 S.946 Henrietta Lacks Enhancing Cancer Research Act of 2019 S.1125 Protect Act S.1895 Lower Health Care Costs Act S.1944 Public Health Funding Restoration Act. HR 3 Elijah E. Cummings Lower Drug Costs Now Act; H.R.4716 I CAN Act; HR 5230 Elijah E. Cummings Family Asthma Act; HR 6201 - Families First Coronavirus Act; HR 6704 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; HR 748 - CARES Act; S. 3548 - CARES Act; S. 1531 - Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; HR 6408 -- To extend the charitable deduction to all taxpayers regardless of whether a taxpayer itemizes deductions in order to encourage and increase charitable giving, and to provide for loans and loan guarantees to certain public charities; HR 7610 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021; HR 7667 Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021; HR 7617 Department of Defense Appropriations Act, 2021; HR 7612 Department of the Interior, Environment, and Related Agencies Appropriations Act, 2021; HR 2468 School-Based Allergies and Asthma Management Program Act; HR 7614 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021; HR 7609 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021; HR 7616 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2021; HR 7608 Department of State, Foreign Operations, and Related Programs Appropriations Act, 2021; H.R.5076 Protecting Seniors Through Immunization Act of 2019; H.R.6561 Improving Social Determinants of Health Act of 2020; HR 6800 HEROES Act; H.R.6935 Protecting the Health of America's Older Adults During COVID-19 and Beyond Act; HR 7286 Quit Because of COVID-19 Act; S. 4775 Delivering Immediate Relief to Americas Families, Schools and Small Businesses Act; S. 4321 The Continuing Small Business Recovery and Paycheck Protection Program Act; S. 4318 The American Workers, Families, and Employers Assistance Act; S. 4317 SAFE TO WORK Act; S. 4322 The Safely Back to School and Back to Work Act; S. 4320 Coronavirus Response Additional Supplemental Appropriations Act, 2020; ;H.R.8061 Community Immunity During COVID-19 Act of 2020;H.R.8406 The Heroes Act; H.R.925 The Heroes Act; S.4557 COVER Act; S.4740 A bill to support public health infrastructure; H.RES.957 Expressing support for the designation of May as "National Asthma and Allergy Awareness Month"; H.R.7011 Pandemic Risk Insurance Act of 2020; H.R.8261 Presumptive Benefits for War Fighters Exposed to Burn Pits and Other Toxins Act of 2020; S.4572 Presumptive Benefits for War Fighters Exposed to Burn Pits and Other Toxins Act of 2020; S.4355 Katherine's Lung Cancer Early Detection and Survival Act of 2020; H.RES.1192 Expressing support for the goals of November National Lung Cancer Awareness Month and for the early detection of lung cancer; H.R.8158 To amend title XVIII of the Social Security Act to waive budget neutrality for oxygen under the Medicare program, and for other purposes.;H.R.7481 RESTART Act; S.4737 A bill to amend the Public Health Service Act to direct the Secretary of Health and Human Services to make grants to covered health departments to increase the rate of recommended immunizations, and for other purposes; S.Res.780 A resolution designating November 2020 as "National Lung Cancer Awareness Month" and expressing support for the early detection of lung cancer; H.R.8623 SAVE for Seniors Act; S.4864 HAPI Act; H.R.8725 HAPI Act; H.R.8595 To nullify the effect of Executive Order 13950 relating to combating race and sex stereotyping; Senate Labor HHS Appropriations bill; Senate Defense Appropriations bill; Senate Transportation, Housing and Urban Development and Related Agencies Appropriations bill; Senate Agriculture, Rural Development, FDA, and Related Agencies Appropriations bill; Senate Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021H.R.133 Consolidated Appropriations Act, 2021; H.J.Res.110 - Extension of Continuing Appropriations Act, 2021

Client expense: $40,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Postal Regulatory Commission, SENATE, Small Business Administration (SBA), Treasury, Dept of, White House Office

H.R. 7286/S.4524, the Quit Because of COVID-19 Act of 2020.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare Access and CHIP Reauthorization Act of 2015 implementation, Medicare physician payment reform, MEDPAC, surgical global payments, ACA implementation, health care reform, health care quality improvement, physician workforce issues, comparative clinical effectiveness research, health information technology, EHR meaningful use, EHR data blocking, Patient-Centered Outcomes Research Institute, MEDCAC, Centers for Medicare & Medicaid Innovation, registry access to Medicare claims data, lung cancer screenings, Agency for Healthcare Research & Quality, graduate medical education, electronic cigarette and cigar regulation, PTAC, meaningful use, congenital heart disease funding, unique device identifiers, medical liability reform, COVID-19 pandemic, tobacco riders in appropriations bills, tobacco regulation in the FDA, price transparency, ECMO coding, Prohibit Smoking in VA Facilities Act (S.2106/HR3700) Resident Physician Shortage Reduction Act (S.348/HR1763), Congenital Heart Futures Reauthorization Act, surprise billing, prior authorization, Women and Lung Cancer Research and Preventive Services Act (S.1107/HR2222), T21 bills, Transcatheter aortic valve replacement (TAVR), Increasing Access to Quality Cardiac Rehabilitation Act (HR.3911), Smoke-Free Schools Act of 2019 (HR.4019/S.1832), Protection for Veterans Burn Pits Exposure Act (HR.4086), The Coronavirus Aid, Relief, and Economic Security Act (H.R.748), Coronavirus Provider Protection Act (H.R.7059), Resident Physician Shortage Reduction Act of 2019 (S. 348/H.R. 1763), Quit Because of COVID-19 Act (H.R.7286), Tobacco to 21 Act (S.1258/H.R.2411), The Local Chamber, Tourism, and 501(c)(6) Protection Act (H.R.6697), Immediate Relief for Rural Facilities and Providers Act (S.3559/H.R.6365), Reversing the Youth Tobacco Epidemic Act of 2019 (H.R.2339), Vaccines Act of 2019 (H.R.2862), Investment in Tomorrow's Pediatric Health Care Workforce Act (S.2443), Protecting People from Surprise Medical Bills Act (H.R.3502), Stopping Appealing Flavors in E-Cigarettes for Kids Act (H.R.1498), Resident Education Deferred Interest (REDI) Act (H.R.1554), Improving Access to Medicare Coverage Act (H.R.1682), Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 (H.R.1854), Women & Lung Cancer Research & Preventive Services Act (H.R.2222), Prevent BLEEDing Act of 2019 (H.R.2550), Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act (H.R.2781), PCORI Reauthorization (H.R.3030), Improving Seniors Timely Access to Care Act (H.R.3107), Keep Physicians Serving Patients Act (H.R.3302), Stopping Appealing Flavors in E-Cigarettes for Kids Act (S.655), Improving Access to Medicare Coverage Act (S.753), Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020 (H.R. 8702/S.5007), Medicare Reimbursement Equity Act of 2020 (S.4932), To amend title XVIII of the Social Security Act to provide for a one-year waiver of budget neutrality adjustments under the Medicare physician fee schedule, and for other purposes (H.R. 8505)

Client expense: $86,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Social Security Administration (SSA)

Ending Nicotine Dependence from Electronic Delivery Systems (End ENDS) Act (H.R. 4264), Reversing the Youth Tobacco Epidemic Act (H.R. 2339/S. 3174), SAFE Kids Act (H.R. 1498/S. 655), Smoke Free Schools Act (S. 1832/H.R. 4019), Tobacco Free Youth Act (S. 1541), Protecting American Lungs Act (H.R. 4742), Quit Because of COVID-19 Act (H.R. 7286), Independent Advisory Committee Review of E-Cigarettes Applications Act (H.R. 8343), e-cigarettes, and premarket application of tobacco products

Client expense: $30,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Education, Dept of, Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19 Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose. Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists. Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals. Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19 Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code. Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be. Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology. Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package. Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments. Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package Opposed passage of the MORE Act H.R. 3884, which would, among other things, remove cannabis from the list of controlled substances under the CSA. Provided comments on a draft Residential Substance Abuse Treatment (RSAT) bill Provided comments on CARA 2.0 legislation, S. 5000, related to prescriber education and curricula grants Joined coalition letter to FDA urging the Commissioner to commence rulemaking to prohibit menthol as characterizing flavor in cigarettes Discussions regarding draft legislation on Medicaid reimbursement for addition treatment providers and repeal of the IMD exclusion in Medicaid for residential addiction treatment Discussions regarding the EASY MAT Act, HR 2281, CBO score Submitted letter of support for S. 4612, the Methamphetamine Response Act, which would declare methamphetamine an emerging drug threst

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19 Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose. Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists. Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals. Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19 Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code. Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be. Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology. Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package. Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments. Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package Opposed passage of the MORE Act H.R. 3884, which would, among other things, remove cannabis from the list of controlled substances under the CSA. Provided comments on a draft Residential Substance Abuse Treatment (RSAT) bill Provided comments on CARA 2.0 legislation, S. 5000, related to prescriber education and curricula grants Joined coalition letter to FDA urging the Commissioner to commence rulemaking to prohibit menthol as characterizing flavor in cigarettes Discussions regarding draft legislation on Medicaid reimbursement for addition treatment providers and repeal of the IMD exclusion in Medicaid for residential addiction treatment Discussions regarding the EASY MAT Act, HR 2281, CBO score Submitted letter of support for S. 4612, the Methamphetamine Response Act, which would declare methamphetamine an emerging drug threst

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19 Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose. Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists. Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals. Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19 Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code. Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be. Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology. Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package. Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments. Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package Opposed passage of the MORE Act H.R. 3884, which would, among other things, remove cannabis from the list of controlled substances under the CSA. Provided comments on a draft Residential Substance Abuse Treatment (RSAT) bill Provided comments on CARA 2.0 legislation, S. 5000, related to prescriber education and curricula grants Joined coalition letter to FDA urging the Commissioner to commence rulemaking to prohibit menthol as characterizing flavor in cigarettes Discussions regarding draft legislation on Medicaid reimbursement for addition treatment providers and repeal of the IMD exclusion in Medicaid for residential addiction treatment Discussions regarding the EASY MAT Act, HR 2281, CBO score Submitted letter of support for S. 4612, the Methamphetamine Response Act, which would declare methamphetamine an emerging drug threst

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19 Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose. Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists. Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals. Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19 Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code. Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be. Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology. Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package. Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments. Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package Opposed passage of the MORE Act H.R. 3884, which would, among other things, remove cannabis from the list of controlled substances under the CSA. Provided comments on a draft Residential Substance Abuse Treatment (RSAT) bill Provided comments on CARA 2.0 legislation, S. 5000, related to prescriber education and curricula grants Joined coalition letter to FDA urging the Commissioner to commence rulemaking to prohibit menthol as characterizing flavor in cigarettes Discussions regarding draft legislation on Medicaid reimbursement for addition treatment providers and repeal of the IMD exclusion in Medicaid for residential addiction treatment Discussions regarding the EASY MAT Act, HR 2281, CBO score Submitted letter of support for S. 4612, the Methamphetamine Response Act, which would declare methamphetamine an emerging drug threst

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19 Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose. Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists. Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals. Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19 Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code. Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be. Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology. Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package. Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments. Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package Opposed passage of the MORE Act H.R. 3884, which would, among other things, remove cannabis from the list of controlled substances under the CSA. Provided comments on a draft Residential Substance Abuse Treatment (RSAT) bill Provided comments on CARA 2.0 legislation, S. 5000, related to prescriber education and curricula grants Joined coalition letter to FDA urging the Commissioner to commence rulemaking to prohibit menthol as characterizing flavor in cigarettes Discussions regarding draft legislation on Medicaid reimbursement for addition treatment providers and repeal of the IMD exclusion in Medicaid for residential addiction treatment Discussions regarding the EASY MAT Act, HR 2281, CBO score Submitted letter of support for S. 4612, the Methamphetamine Response Act, which would declare methamphetamine an emerging drug threst

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19 Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose. Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists. Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals. Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19 Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code. Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be. Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology. Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package. Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments. Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package Opposed passage of the MORE Act H.R. 3884, which would, among other things, remove cannabis from the list of controlled substances under the CSA. Provided comments on a draft Residential Substance Abuse Treatment (RSAT) bill Provided comments on CARA 2.0 legislation, S. 5000, related to prescriber education and curricula grants Joined coalition letter to FDA urging the Commissioner to commence rulemaking to prohibit menthol as characterizing flavor in cigarettes Discussions regarding draft legislation on Medicaid reimbursement for addition treatment providers and repeal of the IMD exclusion in Medicaid for residential addiction treatment Discussions regarding the EASY MAT Act, HR 2281, CBO score Submitted letter of support for S. 4612, the Methamphetamine Response Act, which would declare methamphetamine an emerging drug threst

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Vaping (oral health impact) Congressional Caucus to End the Youth Vaping Epidemic H.R. 2339, the Reversing the Youth Tobacco Epidemic Act of 2019 H.R. 1498, Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) S. 655, Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) H.R. 1854, the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 S. 9, the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 H.R. 3942/S.1253, the Preventing Online Sales of E-Cigarettes to Children Act H.R. 4742, a bill that would impose an excise tax on nicotine H.R. 7286, the Quit Because of COVID-19 Act Rule Characterizing Menthol as an Added Flavor in Tobacco and Vaping Products

Client expense: $640,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Emergency Management Agency (FEMA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Indian Health Service, Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Occupational Safety & Health Administration (OSHA), Office of Science & Technology Policy (OSTP), SENATE, Small Business Administration (SBA), Treasury, Dept of, U.S. Immigration & Customs Enforcement (ICE), Veterans Affairs, Dept of (VA), White House Office

H.R. 7614 FY2021 Labor, Health and Human Services Appropriations Act specifically for increased funding for CDC tobacco control activities. H.R. 7610 FY2021 Agriculture Appropriations Act specifically for adequate funding and continued authority for tobacco control activities. H.R. 2339/H.R. 1498 Legislation to further protect kids from tobacco and nicotine addiction. H.R 7286/S.4524 Quit Because of COVID-19 Act to provide greater Medicaid coverage for tobacco prevention and cessation services.

Client expense: Not reported · Firm income: $10,000

H.R 7286/S.4524 Quit Because of COVID-19 Act to provide greater Medicaid coverage for tobacco prevention and cessation services.

Client expense: Not reported · Firm income: $10,000

H.R. 7614 FY2021 Labor, Health and Human Services Appropriations Act specifically for increased funding for CDC tobacco control activities. H.R. 7610 FY2021 Agriculture Appropriations Act specifically for adequate funding and continued authority for tobacco control activities. H.R. 2339/H.R. 1498 Legislation to further protect kids from tobacco and nicotine addiction. H.R 7286/S.4524 Quit Because of COVID-19 Act to provide greater Medicaid coverage for tobacco prevention and cessation services.

Client expense: Not reported · Firm income: $10,000

Support HR 7286 / S 4524 the Quit Because of COVID-19 Act, which would expand tobacco cessation coverage to ensure all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of proven tobacco cessation treatments at this critical time

Client expense: $72,500 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Bureau of the Census, Centers For Disease Control & Prevention (CDC), Consumer Financial Protection Bureau (CFPB), Defense, Dept of (DOD), Education, Dept of, Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Housing Finance Agency (FHFA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Office of the Comptroller of the Currency (OCC), Postal Regulatory Commission, President of the U.S., SENATE, Social Security Administration (SSA), Treasury, Dept of

Support Medicaid section 1115 demonstrations that will work to mitigate racial disparities rather than making them worse. Oppose policies that increase racial disparities such as pending proposals to impose punitive work requirements on parents with very low incomes in Alabama, Mississippi, Oklahoma, Tennessee, and South Dakota and support programs such as pending and future state section 1115 demonstration proposals to extend postpartum coverage to reduce maternal and infant mortality. Support accelerated scientific advances to improve and sustain the health of all Americans, reduce health disparities, lower healthcare spending, strengthen our food system, improve military readiness, and accelerate discoveries and economic growth Support HR 7286 / S 4524 the Quit Because of COVID-19 Act, which would expand tobacco cessation coverage to ensure all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of proven tobacco cessation treatments at this critical time. Support the invaluable role of the Centers for Disease Control and Prevention (CDC) in containing the COVID-19 virus and resist any efforts that would undermine its mission. Oppose the recent guidance for hospitals to direct daily COVID-19 data reports to HHS via a system managed by a private contractor. Support H.R. 8436, the Equal Health Care for All Act, which would to apply a civil rights frame to the issue of inequitable care. Support an extension of WIC waivers in any COVID-19 stimulus package. USDA waiver authority (first granted by the Families First Act) is essential for enabling remote services. Without these waivers, clinics will have to reopen on October 1 - forcing pregnant women and young kids to show up in-person well before states are ready to safely open clinic doors. Support HR 8061 , the Community Immunity During COVID-19 Act which would provide robust funding to develop, scale, and evaluate local initiatives to promote recommended vaccinations during this pandemic. Support Congress saving jobs and promoting economic recovery by prioritizing comprehensive health coverage in the next COVID-19 legislative package. Support extend Co-Pay assistance support to Medicare Part D beneficiaries for the extent of the pandemic. Support S. 4533, the Anti-Racism in Public Health Act of 2020, which would to provide for public health research and investment into understanding and eliminating structural racism and police violence Support H.R. 8141, to reduce health inequities experienced by individuals who are members of historically racial and ethnic minority groups under State plans under the community mental health services block grant program. Support a bipartisan letter urges the administration to take immediate policy action to mobilize community health workers as part of the COVID-19 response and long-term health recovery. Support H,R, 8474, the Jobs and Justice Act, which is an omnibus bill to advance Black families, with provisions to combat the spread of COVID-19, advance economic and educational opportunities, address health disparities, reform the criminal justice system from end to end, and expand access to the ballot. Support S. 4536 / H.R.7983, the COVID-19 in Corrections Data Transparency Act which would require the collection and reporting of key data on the spread and effect of coronavirus within all of the nations correctional facilities. Support S. 4819, the Health Equity and Accountability Act, a blueprint of smart, bold policy solutions that will eliminate barriers to coverage, expand access to affordable care and strengthen the health care system for all, especially for communities affected by health disparities. Support the Mental Health Justice Act, which creates a grant program to pay for hiring, training, salary, benefits and additional expenses for mental health provider first responder units (these mental health providers will act as a sort of mental health SWAT Team - when 911 is called because someone is in a mental health crisis, they will be the first on the scene to help the individual and can divert them to appropriate community resources); and provides technical assistance from the Disability Rights Section of the Civil Rights Division at DOJ and from the Substance Abuse and Mental Health Services Administration (SAMHSA) (grant recipients will receive technical assistance for the establishment and operation of the program. Additionally, states and localities may apply for technical assistance from SAMHSA/DOJ if they choose to use their own funding for the program costs from another portion of the law enforcement budget). Support S. 4737, the Community Immunity During COVID-19 Act, which directs the Secretary of Health and Human Services to make grants to covered health departments to increase the rate of recommended immunizations. Support an aggressive, bold, effective and comprehensive stimulus package to provide relief for much of the needless suffering and a myriad of areas that is occurring across our nation as a result of the COVID-19 pandemic. Support Public health leaders and policymakers in that they must ensure they are maximizing benefit, treating people equally, providing a clear benefit and prioritizing those who are worst off.

Client expense: $72,500 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Bureau of the Census, Centers For Disease Control & Prevention (CDC), Consumer Financial Protection Bureau (CFPB), Defense, Dept of (DOD), Education, Dept of, Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Housing Finance Agency (FHFA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Office of the Comptroller of the Currency (OCC), Postal Regulatory Commission, President of the U.S., SENATE, Social Security Administration (SSA), Treasury, Dept of

Support Medicaid section 1115 demonstrations that will work to mitigate racial disparities rather than making them worse. Oppose policies that increase racial disparities such as pending proposals to impose punitive work requirements on parents with very low incomes in Alabama, Mississippi, Oklahoma, Tennessee, and South Dakota and support programs such as pending and future state section 1115 demonstration proposals to extend postpartum coverage to reduce maternal and infant mortality. Support HR 7286 / S 4524 the Quit Because of COVID-19 Act, which would expand tobacco cessation coverage to ensure all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of proven tobacco cessation treatments at this critical time. Support extending Co-Pay assistance support to Medicare Part D beneficiaries for the extent of the pandemic. Support an aggressive, bold, effective and comprehensive stimulus package to provide relief for much of the needless suffering and a myriad of areas that is occurring across our nation as a result of the COVID-19 pandemic.

Client expense: $72,500 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Bureau of the Census, Centers For Disease Control & Prevention (CDC), Consumer Financial Protection Bureau (CFPB), Defense, Dept of (DOD), Education, Dept of, Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Housing Finance Agency (FHFA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Office of the Comptroller of the Currency (OCC), Postal Regulatory Commission, President of the U.S., SENATE, Social Security Administration (SSA), Treasury, Dept of

E-cigarette Tax Priority Act (S.2463) Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction (PROTECT) Act (S.1048/H.R.2111) Protecting American Lungs Act of 2019 (H.R. 4742) Protecting American Lungs and Reversing the Youth Tobacco Epidemic Act of 2020 (H.R. 2339) Quell Underage Inhalation of Toxic Substances Act of 2019 (H.R. 4425) Quit Because of COVID-19 Act (HR 7286/S. 4524) Resources to Prevent Youth Vaping Act (S. 3223/H.R. 5721) Reversing the Youth Tobacco Epidemic Act of 2020 (S. 3174) SCOTT Act of 2019 (H.R.2084) Smoke-Free Schools Act of 2019 (S.1832/H.R.4019) Stopping Appealing Flavors in E-Cigarettes for Kids (SAFE Kids) Act (S.655/H.R.1498) Tobacco-Free Youth Act (S.1541) Tobacco Tax Equity Act (S.2517) To amend title 38, U.S. Code, to prohibit smoking on the premises of any facility of the Veterans Health Administration, & for other purposes (S.2106/H.R.3700) Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 (H.R.1854/S.9) Implementation of: The Family Smoking Prevention and Tobacco Control Act (P.L.111-31) The Further Consolidated Appropriations Act of 2020 (P.L. 116-94): Division N, Sec. 603 Minimum age of sale of tobacco products and Sec. 604 Sale of tobacco products to individuals under the age of 21

Client expense: $170,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, Veterans Affairs, Dept of (VA), White House Office

Ban Surprise Billing Act (H.R. 5800) Consumer Protections Against Surprise Medical Bills Act of 2020 (H.R. 5826) Dependent Income Exclusion Act of 2019 (H.R.4417/S.2497) Educating Consumers on the Risks of Short-Term Plans Act of 2019 (H.R.1143) ENROLL Act of 2019 (H.R.1386/S.1905) Family Coverage Act (S.1935) HEARTS Act of 2020 (H.R. 6166) The Heroes Act (H.R. 6800) Home Visiting to Reduce Maternal Mortality and Morbidity Act (H.R.4768) Lower Health Care Costs Act (S.1895) Marketing & Outreach Restoration to Empower Health Education Act (MORE) (H.R.987) No Surprises Act (H.R.3630) The Patient Protection and Affordable Care Enhancement Act (H.R. 1425) Personal Health Investment Today Act (PHIT) (S.680/H.R.1679) Physical Activity Recommendations (PAR) for Americans Act (S.1608/H.R.2891) Pre-existing Conditions Protection Act of 2019 (H.R.692) Protect Act (S.1125) Protecting Access to Post COVID-19 Telehealth Act of 2020 (H.R. 7663) Protecting Americans with Pre-existing Conditions Act of 2019 (H.R.986) Public Health Funding Restoration Act (S.1944/H.R.3447) Quit Because of COVID-19 Act (H.R. 7286) A Resolution Supporting the Designation of April 2019 as "National Donate Life Month"(H.Res 315/S.Res 162) South Asian Heart Health Awareness and Research Act of 2019 (H.R.3131) State Allowance for a Variety of Exchanges Act (SAVE Act) (H.R.1385) States Achieve Medicaid Expansion (S.585) State Health Care Premium Reduction Act (H.R.1425) Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019 (S.1531) Sustaining Outpatient Services Act (H.R. 4838/S.4151) Implementation of: Menu Labeling Physical Activity Guidelines Recommendations Prevention and Public Health Fund (PL 111-148, Sec 4002)

Client expense: $170,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Federal Reserve System, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, Veterans Affairs, Dept of (VA), White House Office

Medicare Access and CHIP Reauthorization Act of 2015 implementation, Medicare physician payment reform, MEDPAC, surgical global payments, ACA implementation, health care reform, health care quality improvement, physician workforce issues, comparative clinical effectiveness research, health information technology, EHR meaningful use, EHR data blocking, Patient-Centered Outcomes Research Institute, MEDCAC, Centers for Medicare & Medicaid Innovation, registry access to Medicare claims data, lung cancer screenings, Agency for Healthcare Research & Quality, graduate medical education, electronic cigarette and cigar regulation, PTAC, meaningful use, congenital heart disease funding, unique device identifiers, medical liability reform, COVID-19 pandemic, tobacco riders in appropriations bills, tobacco regulation in the FDA, price transparency, ECMO coding, Prohibit Smoking in VA Facilities Act (S.2106/HR3700) Resident Physician Shortage Reduction Act (S.348/HR1763), Congenital Heart Futures Reauthorization Act, surprise billing, prior authorization, Women and Lung Cancer Research and Preventive Services Act (S.1107/HR2222), T21 bills, Transcatheter aortic valve replacement (TAVR), Increasing Access to Quality Cardiac Rehabilitation Act (HR.3911), Smoke-Free Schools Act of 2019 (HR.4019/S.1832), Protection for Veterans Burn Pits Exposure Act (HR.4086), The Coronavirus Aid, Relief, and Economic Security Act (H.R.748), Coronavirus Provider Protection Act (H.R.7059), Resident Physician Shortage Reduction Act of 2019 (S. 348/H.R. 1763), Quit Because of COVID-19 Act (H.R.7286), Tobacco to 21 Act (S.1258/H.R.2411), The Local Chamber, Tourism, and 501(c)(6) Protection Act (H.R.6697), Immediate Relief for Rural Facilities and Providers Act (S.3559/H.R.6365), Reversing the Youth Tobacco Epidemic Act of 2019 (H.R.2339), Vaccines Act of 2019 (H.R.2862), Investment in Tomorrow's Pediatric Health Care Workforce Act (S.2443), Protecting People from Surprise Medical Bills Act (H.R.3502), Stopping Appealing Flavors in E-Cigarettes for Kids Act (H.R.1498), Resident Education Deferred Interest (REDI) Act (H.R.1554), Improving Access to Medicare Coverage Act (H.R.1682), Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 (H.R.1854), Women & Lung Cancer Research & Preventive Services Act (H.R.2222), Prevent BLEEDing Act of 2019 (H.R.2550), Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act (H.R.2781), PCORI Reauthorization (H.R.3030), Improving Seniors Timely Access to Care Act (H.R.3107), Keep Physicians Serving Patients Act (H.R.3302), Stopping Appealing Flavors in E-Cigarettes for Kids Act (S.655), Improving Access to Medicare Coverage Act (S.753)

Client expense: $143,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE, Social Security Administration (SSA)

H.R. 2339: Reversing the Youth Tobacco Epidemic Act of 2019 H.R. 7286: Quit Because of COVID-19 ACT of 2020

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction Act - HR 2111/S 1048 Quit Because of COVID Act - HR 7286

Client expense: $219,650 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related asthma; COPD; influenza; lung cancer; pneumonia; tuberculosis and other lung diseases; Issues related to lung disease treatment, prevention and research; Issues related to the President's Budget; Issues related to COVID-19 Response; Issues related to telehealth; H.R.2021 Investing for the People Act of 2019 H.R.2508 Better Respiration through Expanding Access to Tele-Health Act; HR 6201 - Families First Coronavirus Act; HR 6704 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; HR 748 - CARES Act; S. 3548 - CARES Act; HR 7617 Department of Defense Appropriations Act, 2021; HR 7614 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021; HR 6800 HEROES Act: HR 7286 Quit Because of COVID-19;H.RES.1192 Expressing support for the goals of November National Lung Cancer Awareness Month and for the early detection of lung cancer.

Client expense: $40,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Postal Regulatory Commission, SENATE, Small Business Administration (SBA), Treasury, Dept of, White House Office

Issues related to lung disease treatment, prevention and research; public health; Issues related to tobacco cessation; Issues related to health inequities; Issues related to the President's Budget; Issues related to Medicaid waivers; Issues related to the Affordable Care Act; Issues related to oxygen; Issues related to access to healthcare; Issues related to COVID-19 Response; H.R.2508 Better Respiration through Expanding Access to Tele-Health Act; HR 3 Elijah E. Cummings Lower Drug Costs Now Act; S 2543 Prescription Drug Pricing Reduction Act of 2019; S 2911 Seniors Prescription Drug Relief Act of 2019; HR 7610 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021; HR 7667 Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021; HR 7617 Department of Defense Appropriations Act, 2021; HR 7612 Department of the Interior, Environment, and Related Agencies Appropriations Act, 2021; HR 7614 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021; HR 7609 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021; HR 7616 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2021; HR 7608 Department of State, Foreign Operations, and Related Programs Appropriations Act, 2021; HR 4945 Safeguarding Medicare Access to Respiratory Therapy Act of 2019; HR 6800 HEROES Act; HR 7286 Quit Because of COVID-19 Act; S. 4775 Delivering Immediate Relief to Americas Families, Schools and Small Businesses Act; S. 4321 The Continuing Small Business Recovery and Paycheck Protection Program Act; S. 4318 The American Workers, Families, and Employers Assistance Act; S. 4317 SAFE TO WORK Act; S. 4322 The Safely Back to School and Back to Work Act; S. 4320 Coronavirus Response Additional Supplemental Appropriations Act, 2020; H.R.8406 The Heroes Act; H.R.925 The Heroes Act; S.4557 COVER Act; H.R.6201 Families First Coronavirus Response Act; H.R.748 CARES Act; S.4355 Katherine's Lung Cancer Early Detection and Survival Act of 2020; H.R.8158 To amend title XVIII of the Social Security Act to waive budget neutrality for oxygen under the Medicare program, and for other purposes;

Client expense: $40,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Postal Regulatory Commission, SENATE, Small Business Administration (SBA), Treasury, Dept of, White House Office

Issues related to lung disease treatment, prevention and research; public health; Issues related asthma; COPD; influenza; lung cancer; pneumonia; tuberculosis and other lung diseases; Issues related to tobacco cessation; Issues related to the Affordable Care Act; Issues related to the Childrens Health Insurance Program; Issues related to the President's Budget; Issues related to telehealth; Issues related to changing federal poverty line calculation; Issues related to COVID-19 Response;; H.R.986 Protecting Americans with Preexisting Conditions Act of 2019 H.R.987 Strengthening Health Care and Lowering Prescription Drug Costs Act H.R.1010 To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect. H.R.1385 SAVE Act H.R.1386 ENROLL Act of 2019 H.R.1425 State Health Care Premium Reduction Act H.R.1499 Protecting Consumer Access to Generic Drugs Act of 2019 H.R.1884 Protecting Pre-Existing Conditions and Making Health Care More Affordable Act of 2019 H.R.2508 Better Respiration through Expanding Access to Tele-Health Act;H.R.2862 VACCINES Act of 2019; H.R.3630 No Surprises Act H.R.4622 Family Asthma Act S.466 Protecting Americans with Pre-existing Conditions Act of 2019 S.946 Henrietta Lacks Enhancing Cancer Research Act of 2019 S.1125 Protect Act S.1895 Lower Health Care Costs Act S.1944 Public Health Funding Restoration Act. HR 3 Elijah E. Cummings Lower Drug Costs Now Act; H.R.4716 I CAN Act; HR 5230 Elijah E. Cummings Family Asthma Act; HR 6201 - Families First Coronavirus Act; HR 6704 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; HR 748 - CARES Act; S. 3548 - CARES Act; S. 1531 - Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; HR 6408 -- To extend the charitable deduction to all taxpayers regardless of whether a taxpayer itemizes deductions in order to encourage and increase charitable giving, and to provide for loans and loan guarantees to certain public charities; HR 7610 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021; HR 7667 Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021; HR 7617 Department of Defense Appropriations Act, 2021; HR 7612 Department of the Interior, Environment, and Related Agencies Appropriations Act, 2021; HR 2468 School-Based Allergies and Asthma Management Program Act; HR 7614 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021; HR 7609 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2021; HR 7616 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2021; HR 7608 Department of State, Foreign Operations, and Related Programs Appropriations Act, 2021; H.R.5076 Protecting Seniors Through Immunization Act of 2019; H.R.6561 Improving Social Determinants of Health Act of 2020; HR 6800 HEROES Act; H.R.6935 Protecting the Health of America's Older Adults During COVID-19 and Beyond Act; HR 7286 Quit Because of COVID-19 Act; S. 4775 Delivering Immediate Relief to Americas Families, Schools and Small Businesses Act; S. 4321 The Continuing Small Business Recovery and Paycheck Protection Program Act; S. 4318 The American Workers, Families, and Employers Assistance Act; S. 4317 SAFE TO WORK Act; S. 4322 The Safely Back to School and Back to Work Act; S. 4320 Coronavirus Response Additional Supplemental Appropriations Act, 2020; ;H.R.8061 Community Immunity During COVID-19 Act of 2020;H.R.8406 The Heroes Act; H.R.925 The Heroes Act; S.4557 COVER Act; S.4740 A bill to support public health infrastructure; H.RES.957 Expressing support for the designation of May as "National Asthma and Allergy Awareness Month"; H.R.7011 Pandemic Risk Insurance Act of 2020; H.R.8261 Presumptive Benefits for War Fighters Exposed to Burn Pits and Other Toxins Act of 2020; S.4572 Presumptive Benefits for War Fighters Exposed to Burn Pits and Other Toxins Act of 2020; S.4355 Katherine's Lung Cancer Early Detection and Survival Act of 2020; H.RES.1192 Expressing support for the goals of November National Lung Cancer Awareness Month and for the early detection of lung cancer; H.R.8158 To amend title XVIII of the Social Security Act to waive budget neutrality for oxygen under the Medicare program, and for other purposes.;H.R.7481 RESTART Act; S.4737 A bill to amend the Public Health Service Act to direct the Secretary of Health and Human Services to make grants to covered health departments to increase the rate of recommended immunizations, and for other purposes;

Client expense: $40,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Postal Regulatory Commission, SENATE, Small Business Administration (SBA), Treasury, Dept of, White House Office

Issues related to lung disease treatment and prevention, and public health; Issues related to tobacco cessation; Issues related to smokefree air; Issues related to Tobacco 21; Issues related to the Tobacco Control Act: Issues related to tobacco smuggling; Issues related to the Affordable Care Act; Issues related to the President's Budget; Issues related to tobacco prevention; Issues relating to youth cessation research; Issues related to COVID-19 Response; H.R.293 Youth Vaping Prevention Act of 2019 H.R.1498 SAFE Kids Act H.R.1854 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 H.R.2084 SCOTT Act of 2019 H.R.2111 PROTECT Act H.R.2339 Reversing the Youth Tobacco Epidemic Act of 2019 H.R.2411 Tobacco to 21 Act H.R.3700 To amend title 38, United States Code, to prohibit smoking on the premises of any facility of the Veterans Health Administration, and for other purposes. H.R.4249 Stop Vaping Ads Act of 2019 H.R.4425 Quell Underage Inhaling of Toxic Substances Act of 2019 S.9Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 S.616 E-Cigarette Youth Protection Act S.655 SAFE Kids Act S.1048 Preventing Opportunities for Teen E-Cigarette and Tobacco Addiction S.1253 Preventing Online Sales of E-Cigarettes to Children Act S.1258 Tobacco to 21 Act; S.1832 Smoke-Free Schools Act of 2019 S.2106 A bill to amend title 38, United States Code, to prohibit smoking on the premises of any facility of the Veterans Health Administration, and for other purposes. S.2463 E-Cigarette Tax Parity Act S.2517 Tobacco Tax Equity Act of 2019 S.2519 ENND Act S.2550 No Tax Subsidies for E-Cigarette and Tobacco Ads Act S 2550 No Tax Subsidies for E-Cigarette and Tobacco Ads Act HR 4624 Ending Nicotine Dependence from Electronic Nicotine Delivery Systems Act of 2019 HR 4742 To amend the Internal Revenue Code of 1986 to impose a tax on nicotine used in vaping, etc. H.R.5005 Preventing Vape Use Act H.R.5482 PREVENT Act of 2020 S.3096 PREVENT Act of 2020; HR 7610 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021; HR 7667 Commerce, Justice, Science, and Related Agencies Appropriations Act, 2021; HR 7617 Department of Defense Appropriations Act, 2021; HR 7614 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021; HR 6800 HEROES Act; HR 7286 Quit Because of COVID-19 Act; S. 4775 Delivering Immediate Relief to Americas Families, Schools and Small Businesses Act

Client expense: $40,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Federal Reserve System, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Postal Regulatory Commission, SENATE, Small Business Administration (SBA), Treasury, Dept of, White House Office

Gun violence prevention research funding Child product safety Child passenger safety COVID-19 pandemic response for AI/AN communities Child care supplemental funding Providing Americans Insured Days of Leave Act (HR 6442 / S 3513) Special Diabetes Program for Indians Reauthorization Act (S 3937) Maternal, Infant, and Early Childhood Home Visiting Program funding Sudden Unexpected Infant Death (HR 2271 / S 1130) Infant sleep product safety Lead exposure prevention Regulation of air pollutants Food additive safety Paid family leave Climate change IHS funding Tribal Health Data Improvement Act (HR 7948 / S 4562) Child Abuse Prevention and Treatment Act reauthorization CAPTA Plans of safe care grants Family First Prevention Services Act implementation Issues related to the COVID-19 pandemic and providing supports for the child welfare community Emergency Funding for Child Protection Act (S 3660) Child Welfare Emergency Funding Act (S 4172) Supporting Foster Youth and Families through the Pandemic Act (HR 7947) Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act (HR 6800) The Informing Grandfamilies Act Standards in CBP Custody, S. 2135 Standards in ICE Family Detention Standards in ORR Custody Public Charge Child Nutrition Reauthorization/WIC SNAP Mental Health for Children OTC Drug Reform H.R. 6, DREAM Act Family Separation and Detention CARE for Families Act HR 3107 WIC Act Keep Families Together Act Breastfeeding Peer Counseling Program Public Health Preparedness and Response Research for Pregnant and Lactating Women Palliative Care and Hospice Education and Training Act (S. 2080) Dietary Guidelines Child Poverty HEROES Act Senate 4.0 Coronavirus Response Legislation Asylum Child Poverty Reduction Act Suicide Prevention Dr Lorna Breen Health Care Provider Protection Act S. 4349 CBP Medical Services Contract Child Nutrition Waivers Eviction Moratorium Quit Because of COVID-19 Act (H.R. 7286/ S. 4524) Pediatric Subspecialty Loan Repayment Program FY 2021 Appropriations 2020 Census Deadline Extensions Act (S. 4571) COVID-19 Relief Legislation Mainstreaming Addiction Treatment Act (H.R. 2482/S. 2074) Regulation of Tobacco Products Research Investment to Spark the Economy (RISE) Act (H.R. 7308) Childhood immunizations, including an amendment by the Department of Health and Human Services (HHS) to the PREP Act to allow pharmacists to administer immunizations to children aged three to 18 years old COVID-19 vaccine, the importance of following safety and testing protocols, and the need to include children in clinical vaccine trials FY2021 National Defense Authorization Act (NDAA), including support for provisions to halt the reduction or realignment of military medical personnel billets and transformation of the Military Health System/military medical treatment facilities VACCINES Act and related issues around combatting vaccine hesitancy and misinformation Payment for vaccine administration and reform to the Vaccines for Children (VFC) Program Federal funding for K-12 education in response to COVID-19 FY 2021 appropriations Requesting the collection and regular reporting of data on race and ethnicity by the Social Security Administration (SSA) Addressing the needs of students with disabilities in light of COVID-19 12-Month Continuous Medicaid/CHIP Eligibility Medicaid Work Requirements Medicaid Block Grants Medicaid Per Capita Caps Section 1115 Medicaid Waivers Medicaid Payment Parity Increase to Medicaid FMAP During COVID-19 Establish an automatic FMAP increase tied to state economic indicators S. 4108, Coronavirus Medicaid Response Act HR 6159, the Kids Access to Primary Care Act The Ensuring Access for Womens and Childrens Act, S. 4088. Medicaid Maintenance of Effort (MOE) Protections Comprehensive Access to Robust Insurance Now Guaranteed (CARING) for Kids Act (H.R.6151) H.R.6098 to Expand State CHIP Eligibility Delaying the CHIP FMAP Decrease H.R.6797/S.3881 - CHIPPER Act Medicaid Fiscal Accountability Rule Maternal Health H.R. 4995 Helping Moms Act Expanding Medicaid to 12 Months Post-Partum Medicaid Premiums and Cost Sharing Helping Families Access Pediatric Care Act of 2020 Medicaid Payment for Eligibility Workers Expanding the use of Telehealth in Medicaid/CHIP/Private Insurance Allow for the home and other secure locations as originating (patient) and distant (provider) sites in telehealth Waive telehealth cost-sharing for patients in telehealth Pay for telehealth care visits at parity with that of in-person visits Allow telehealth care for both new and established patients Expanding Capacity for Health Outcomes (ECHO) Act of 2019 (S 1618/HR 5199) Including Preventive Medicine Service Codes to be Eligible for Telehealth Increased Access To Broadband to Expand Telehealth Services Financial Relief to Medicaid Providers Financial Relief for Pediatricians Provider Relief Fund Expanding Provider Relief Fund Eligibility to Those Pediatricians Who Received a Small Medicare Allotment COVID-19 Response Targeted allocation of funds to primary care physician practices. Expand existing alternative payment models for primary care Fully implementing the 2021 outpatient E/M changes. Immediately implement the vaccine administration payment increases proposed in the 2021 MPFS. VACCINES Act, H.R. 2862 Expand VFC to separate CHIP Programs

Client expense: $230,000 · Firm income: Not reported

Government targets: Administration for Children & Families (ACF), Agriculture, Dept of (USDA), Bureau of Citizenship & Immigration Services (BCIS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Federal Aviation Administration (FAA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Indian Health Service, Natl Highway Traffic Safety Administration (NHTSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE)

Ending Nicotine Dependence from Electronic Delivery Systems (End ENDS) Act (H.R. 4264), Reversing the Youth Tobacco Epidemic Act (H.R. 2339/S. 3174), SAFE Kids Act (H.R. 1498/S. 655), Smoke Free Schools Act (S. 1832/H.R. 4019), Tobacco Free Youth Act (S. 1541), Protecting American Lungs Act (H.R. 4742), Quit Because of COVID-19 Act (H.R. 7286), Independent Advisory Committee Review of E-Cigarettes Applications Act (H.R. 8343), e-cigarettes, and premarket application of tobacco products

Client expense: $60,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Education, Dept of, Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

Vaping Policy, H.R. 7286- The Quit Because of COVID-19 Act, S. 4524- The Quit Because of COVID-19 Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Lobbying Report: July 1 - September 30, 2020 Legislation H.R. 6800 Health and Economic Recovery Omnibus Emergency Solutions Act or the HEROES Act H.R. 1854 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 (Lobbying activities related to opposing exemption of cigars from FDA oversight) S. 9 Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 (Lobbying activities related to opposing exemption of cigars from FDA oversight) Senate FY 2021 Appropriations for the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies (Lobbying activities related to FY 2021 appropriations for the Food and Drug Administration and protecting FDAs authority to oversee all tobacco products) H.R. 7610 FY 2021 Appropriations for the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies (Lobbying activities related to FY 2021 appropriations for the Food and Drug Administration and protecting FDAs authority to oversee all tobacco products) Senate FY 2021 Appropriations for the Departments of Labor, Health and Human Services, and Education, and Related Agencies (Lobbying activities related to FY 2021 appropriations for the Centers for Disease Control and Prevention) H.R. 7614 FY 2021 Appropriations for the Departments of Labor, Health and Human Services, and Education, and Related Agencies (Lobbying activities related to FY 2021 appropriations for the Centers for Disease Control and Prevention) Senate FY 2021 Appropriations for the Department of State, Foreign Operations, and Related Programs Appropriations Act H.R. 7608 Consolidated Appropriations Act (Lobbying activities related to FY 2021 appropriations for the Food and Drug Administration and protecting FDAs authority to oversee all tobacco products) H.R. 7617 Consolidated Appropriations Act (Lobbying activities related to FY 2021 appropriations for the Centers for Disease Control and Prevention) S. 655 Stopping Appealing Flavors in E-Cigarettes for Kids Act (Lobbying activities related to curbing the use of flavors in tobacco products, including electronic cigarettes and cigars) S. 3174 Reversing the Youth Tobacco Epidemic Act of 2020 (Lobbying activities related to the entire bill) S. 1253/H.R. 3942 Preventing Online Sales of E-Cigarettes to Children Act (Lobbying activities related to applying requirements relating to delivery sales of cigarettes to delivery sales of electronic nicotine delivery systems) S. 2463 E-Cigarette Tax Parity Act (Lobbying activities related to the entire bill) S. 2517 Tobacco Tax Equity Act (Lobbying activities related to the entire bill) S. 3223 Resources to Prevent Youth Vaping Act H.R. 6637 Health Equity and Accountability Act of 2020 Senate Health Equity and Accountability Act of 2020 H.R. 7286/ S. 4524 Quit Because of COVID-19 Act H.R. 8343 The Independent Advisory Committee Review of E-Cigarette Applications Act S. 4440 Social Determinants of Health Act H.R. 8137 Accurate Reporting of Smoking Variants Act of 2020 S. 4740 A bill to support public health infrastructure Issues Prevention and Public Health Fund (Lobbying activities related to preserving the Fund) Tobaccos role in health disparities FDA regulation of tobacco products Flavored tobacco products E-Cigarettes E-Cigarette Marketing Preventing tobacco use by kids Online sales of tobacco products Misleading social media marketing by tobacco companies Funding for CDC Office on Smoking and Health Public health funding and COVID-19 response Health disparities and COVID-19 Medicaid and tobacco cessation Agencies Visited US House of Representatives US Senate Centers for Disease Control and Prevention

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE

H.R. 7286, the Quit Because of COVID-19 Act of 2020; S. 4524, the Quit Because of COVID-19 Act of 2020.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 7286, the Quit Because of COVID-19 Act

Client expense: $280,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Science Foundation (NSF), Natl Security Agency (NSA), SENATE, Veterans Affairs, Dept of (VA)

Support H.R. 7286, the Quit Because of COVID-19 Act. Opposition to any provisions in the FY21 Agriculture appropriations bill that would weaken FDAs authority over regulation of tobacco products.

Client expense: $16,051 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of the Vice President of the United States, SENATE, Vice President of the U.S., White House Office

Vaping (oral health impact) Congressional Caucus to End the Youth Vaping Epidemic H.R. 2339, the Reversing the Youth Tobacco Epidemic Act of 2019 H.R. 1498, Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) S. 655, Stopping Appealing Flavors in E-Cigarettes for Kids Act (SAFE Kids Act) H.R. 1854, the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 S. 9, the Traditional Cigar Manufacturing and Small Business Jobs Preservation Act of 2019 H.R. 3942, the Preventing Online Sales of E-Cigarettes to Children Act H.R. 4742, a bill that would impose an excise tax on nicotine H.R. 7286, the Quit Because of COVID-19 Act

Client expense: $610,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Environmental Protection Agency (EPA), Federal Communications Commission (FCC), Federal Emergency Management Agency (FEMA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Indian Health Service, Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Occupational Safety & Health Administration (OSHA), Office of Science & Technology Policy (OSTP), SENATE, Small Business Administration (SBA), Treasury, Dept of, U.S. Immigration & Customs Enforcement (ICE), Veterans Affairs, Dept of (VA), White House Office

Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19 Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose. Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists. Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals. Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19 Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code. Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be. Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology. Submitted comments on the Department of Labors (DOL) proposed update to the 2020 MHPAEA Self-Compliance Tool and commended DOL for the updates to the Self-Compliance Tool, while offering several detailed recommendations to clarify and strengthen the tool. Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package. Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments. Sent a letter to the Secretary of Health and Human Services, Alex Azar, requesting his support for a waiver of at least two years of the Health and Human Services (HHS) Office of the Inspector General (OIG) interpretation of the Anti-Kickback Statute and Civil Monetary Penalties as applied to the implementation of contingency management for the treatment of addiction. Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package Supported House Resolution 1057 that would express the sense of the House of Representatives that investments in mental health care and substance use disorder care are necessary to address the high prevalence of those suffering from behavioral health conditions. It also recognizes the need for health care reform to integrate mental health care and substance use disorder treatment in the health care system. Supported HR 7859, the Stregthening Behavioral Health Supports for Schools Act, that would establish in the Substance Abuse and Mental Health Services Administration a Center for School Behavioral Health Technical Assistance Informational discussions with CMS regarding coverage of digital therapeutics for addiction treatment

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19 Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose. Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists. Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals. Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19 Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code. Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be. Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology. Submitted comments on the Department of Labors (DOL) proposed update to the 2020 MHPAEA Self-Compliance Tool and commended DOL for the updates to the Self-Compliance Tool, while offering several detailed recommendations to clarify and strengthen the tool. Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package. Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments. Sent a letter to the Secretary of Health and Human Services, Alex Azar, requesting his support for a waiver of at least two years of the Health and Human Services (HHS) Office of the Inspector General (OIG) interpretation of the Anti-Kickback Statute and Civil Monetary Penalties as applied to the implementation of contingency management for the treatment of addiction. Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package Supported House Resolution 1057 that would express the sense of the House of Representatives that investments in mental health care and substance use disorder care are necessary to address the high prevalence of those suffering from behavioral health conditions. It also recognizes the need for health care reform to integrate mental health care and substance use disorder treatment in the health care system. Supported HR 7859, the Stregthening Behavioral Health Supports for Schools Act, that would establish in the Substance Abuse and Mental Health Services Administration a Center for School Behavioral Health Technical Assistance Informational discussions with CMS regarding coverage of digital therapeutics for addiction treatment

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs. Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period. Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019. Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers. Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes. Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19 Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose. Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists. Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals. Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19 Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code. Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be. Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology. Submitted comments on the Department of Labors (DOL) proposed update to the 2020 MHPAEA Self-Compliance Tool and commended DOL for the updates to the Self-Compliance Tool, while offering several detailed recommendations to clarify and strengthen the tool. Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package. Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments. Sent a letter to the Secretary of Health and Human Services, Alex Azar, requesting his support for a waiver of at least two years of the Health and Human Services (HHS) Office of the Inspector General (OIG) interpretation of the Anti-Kickback Statute and Civil Monetary Penalties as applied to the implementation of contingency management for the treatment of addiction. Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package Supported House Resolution 1057 that would express the sense of the House of Representatives that investments in mental health care and substance use disorder care are necessary to address the high prevalence of those suffering from behavioral health conditions. It also recognizes the need for health care reform to integrate mental health care and substance use disorder treatment in the health care system. Supported HR 7859, the Stregthening Behavioral Health Supports for Schools Act, that would establish in the Substance Abuse and Mental Health Services Administration a Center for School Behavioral Health Technical Assistance Informational discussions with CMS regarding coverage of digital therapeutics for addiction treatment

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)